A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
Launched by ASTRAZENECA · Aug 12, 2008
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Persisting symptoms of GORD despite previous treatment with a full dose proton pump inhibitor
- • informed consent
- • over 18 years of age
- Exclusion Criteria:
- • Current course of Proton Pump inhibitor treatment for more than 8 weeks prior to enrolment in the study
- • More than 1 other course of PPI treatment in the previous 12 month
- • previous use of esomeprazole
- • presence of alarm symptoms
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Buenos Aires, , Argentina
Barquisimeto, , Venezuela
Caracas, , Venezuela
San Cristobal, , Venezuela
Bogota, , Colombia
Santiago De Chile, , Chile
Barranquilla, , Colombia
Vina Del Mar, , Chile
Temuco, , Chile
Medellin, , Colombia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
